Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Accured ExpensesChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Cash from Financing Activities (2019 - 2024)

Historic Cash from Financing Activities for Bioadaptives (BDPT) over the last 6 years, with Q4 2024 value amounting to $194115.0.

  • Bioadaptives' Cash from Financing Activities changed N/A to $194115.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $294115.0, marking a year-over-year decrease of 1810.67%. This contributed to the annual value of $326211.0 for FY2024, which is 2588.02% up from last year.
  • Bioadaptives' Cash from Financing Activities amounted to $194115.0 in Q4 2024.
  • Bioadaptives' 5-year Cash from Financing Activities high stood at $194115.0 for Q4 2024, and its period low was $12582.0 during Q2 2020.
  • In the last 5 years, Bioadaptives' Cash from Financing Activities had a median value of $52000.0 in 2021 and averaged $70610.0.
  • Per our database at Business Quant, Bioadaptives' Cash from Financing Activities skyrocketed by 49608.97% in 2021 and then tumbled by 5748.75% in 2022.
  • Quarter analysis of 5 years shows Bioadaptives' Cash from Financing Activities stood at $44931.0 in 2020, then increased by 15.73% to $52000.0 in 2021, then plummeted by 35.81% to $33377.0 in 2022, then surged by 403.64% to $168100.0 in 2023, then rose by 15.48% to $194115.0 in 2024.
  • Its Cash from Financing Activities was $194115.0 in Q4 2024, compared to $100000.0 in Q3 2024 and $168100.0 in Q3 2023.